Imaging the Nigrostriatal Pathway in Patients with Idiopathic Normal Pressure Hydrocephalus and Parkinsonism
Objective: To investigate the nigrostriatal pathway in iNPH patients with clinical parkinsonism, employing dopaminergic transporter (DAT) and nigrosome imaging. Background: Patients with idiopathic Normal Pressure…Decoding non-IPD Parkinsonism – A Comparative Analysis of Atypical and Secondary Parkinsonism
Objective: Using precise diagnostic criteria, the single-center observational study aims to evaluate the clinical profiles of non-IPD parkinsonism, specifically identifying crucial clinical clues for discriminating…Perry Syndrome due to a DCTN1 novel variant
Objective: To report the clinical features of a patient with Perry syndrome (PS) due to a heterozygous novel pathogenic variant in the DCTN1 gene. Background:…Immunomodulatory Effects Of Covid-19 Vaccination On Inflammatory And Neurotrophic Factors In Parkinson’s Disease: Insights From Clinical Subtypes
Objective: This study investigates the impact of COVID-19 vaccination on levels of interleukin 6 (IL-6) and brain-derived neurotrophic factor (BDNF) in patients with Parkinson's disease…The course of cognitive impairment in Parkinson’s disease patients with Сovid-19
Objective: A comparative analysis of the characteristics of cognitive impairment in Parkinson's disease patients with and without Сovid-19. Background: Covid-19 infection strongly affects the central…Incidence and Prevalence of Parkinson’s Disease Among United States Medicare Beneficiaries by Age, Sex, Race/Ethnicity, and Neighborhood Socioeconomic Status 2014-2021
Objective: To evaluate the trends and differences in incidence and prevalence of Parkison's disease (PD) in Medicare beneficiaries between 2014-2021 across different demographics. Background: The…Effect of various mGlu2 and mGlu2/3 activators on parkinsonism: a sub-analysis in the MPTP-lesioned primate
Objective: To evaluate the effect of the metabotropic glutamate 2/3 (mGlu2/3) orthosteric activators (OAs) LY-354,740 and LY-404,039, as well as the effects of the metabotropic…Cerebral metabolic network in PLA2G6-associated parkinsonism
Objective: To characterize the cerebral metabolic network in PLA2G6-associated parkinsonism (PLA2G6-P). Background: PLA2G6-associated neurodegeneration is known as a continuum of phenotypes. Patients with late-onset PLA2G6-associated…Rapidly Progressive Pallidopyramidal Syndrome related to Parkin gene mutation
Objective: To describe a case of rapidly progressive Pallidopyramidal syndrome related to Parkin gene mutation. Background: Parkin gene mutations are most commonly found in autosomal…Expanding Diversity of Parkinson’s Disease and Related Disorders Genetic Data: from the Global Parkinson’s Genetics Program
Objective: To expand the research dataset for Parkinson’s Disease (PD) and related disorders by including >50,000 participants globally who have been genotyped or whole genome…
- « Previous Page
- 1
- …
- 31
- 32
- 33
- 34
- 35
- …
- 405
- Next Page »